



04/09/97

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5/A  
Dey  
4/30/97

Applicants: Elazer R. Edelman, Aruna Nathan, and Matthew A. Nugent

Serial No: 08/458,978

Art Unit: 1808

RECEIVED  
APRIL  
MAR 23 1997

Filing date: June 2, 1995

Examiner: D. Naff

GROUP 1800

For: Inhibition of Vascular Occlusion Following Intervention

Assistant Commissioner of Patents  
Washington, D.C. 20231

## AMENDMENT

Sir:

Responsive to the Office Action mailed January 16, 1997, please amend the application as follows. An Information Disclosure Statement and appropriate fee for consideration after issuance of an office action on the merits will be forwarded shortly.

## In the Claims

Sub B'  
A1

1. (amended) A method of inhibiting [smooth muscle cell proliferation or] mechanisms involved in restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof (without needing restoration of the endothelial cell lining of the blood vessel), comprising:

implanting a biocompatible matrix having seeded therein or thereon dissociated endothelial cells at a site [near] adjacent to [or at] the injury to [or blockage of] vascular tissue, wherein the endothelial cells are provided in an amount effective to inhibit smooth muscle cell proliferation at the site of the injury.

In re application of: Elazer R. Edelman, Aruna Nathan and Matthew A. Nugent

Serial No. **51776 U.S. PTO** 08/458,978Filed: **04/09/97** June 2, 1995

For: INHIBITION OF VASCULAR OCCLUSION FOLLOWING INTERVENTION

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☒ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	18	MINUS	20	= 0	X 11 =	\$	x22=	\$
INDEP	2	MINUS	3	= 0	x 40 =	\$	x80 =	\$
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+130	\$	+260	\$
					TOTAL ADDIT. FEE	\$	or TOTAL	\$

\* If the entry in Col.1 is less than the entry in Col.2, write "0" in Col.3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col.1 of a prior amendment or the number of claims originally filed.

- ☐ Please charge my Deposit Account No. 01-2507 amount of \$ . A duplicate copy of this sheet is attached.
- ☐ A check in the amount of \$ is attached.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Patrea L. Pabst, Reg. No. 31,284